Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of human urine kininogenase for preparing medicine to treat acute coronary syndromes

A technique for urinary kallikrein and coronary artery disease, which is applied in the field of preparation of drugs for the treatment of acute coronary artery disease, and can solve problems such as unsatisfactory treatment of angina pectoris and short-acting effects

Active Publication Date: 2005-07-06
GUANGDONG TECHPOOL BIO-PHARMA CO LTD
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the most effective treatment for angina pectoris is to take nitroglycerin tablets, but nitroglycerin is quick-acting but short-acting, and it cannot meet the treatment of angina pectoris.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] Example 1 Preparation of human urinary kininogenase dry powder injection

[0013] Take filter-sterilized human urinary kininogenase 150PNA units, add 7.5 grams of mannitol, 2 grams of dextran 40, and 5 grams of sodium citrate to dissolve, adjust the pH to neutral, add water for injection to 500 ml, sterile filter, divide Put it in 1000 ampoules, and freeze-dry it under aseptic conditions.

Embodiment 2

[0014] Example 2 Preparation of human urinary kininogenase injection

[0015] Take filtered sterilized human urinary kininogenase dissolved in 150 PNA units, adjust the pH to neutral, add water for injection to 500 ml, add sodium chloride to adjust isotonicity, filter aseptically, divide into 1000 ampoules, and obtain.

Embodiment 3

[0016] Example 3 Effect of Human Urinary Kallikrein on Experimental Myocardial Ischemia and Myocardial Oxygen Metabolism in Dogs

[0017] experimental method

[0018] Myocardial ischemia model was made by injecting pituitrin. 24 healthy domestic dogs weighing 10-15kg were selected, divided into half male and half male, and randomly divided into 6 groups: blank control group (normal saline); pituitary hormone group (3U / kg); -3 PNAu); human urinary kininogenase II group (3×10 -3 PNAu); human urinary kininogenase III group (6×10 -3 PNAu); nitroglycerin treatment group (5mg / kg). Vasopressin 3U / kg was slowly injected intravenously within 1 minute, and each dose of human urinary kininogenase and nitroglycerin was injected intravenously immediately after the injection of pituitary hormone.

[0019] Anesthetized by intravenous injection of pentobarbital sodium 30mg / kg, the dorsal position was fixed, the tracheotomy was intubated, and an electric ventilator was connected for artifi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the pharmaceutical use of human urinary kallikrein in the treatment of acute coronary artery disease and pharmaceutical composition prepared by the method. Human urinary kallikrein of the invention has an evident therapeutic function for the acute coronary artery disease. In general, it is used by preparing the pharmaceutical composition to freeze dried powder injection and injection liquid.

Description

technical field [0001] The present invention relates to the field of medicinal chemistry. Specifically, the present invention relates to a new medical application of human urinary kallikrein, that is, the application of human urinary kallikrein in the preparation of medicines for treating acute coronary artery disease. Background technique [0002] Cardiovascular disease has become the number one killer of human health in the 21st century, the most dangerous of which is acute coronary syndrome (ACS). ACS includes unstable angina and acute myocardial infarction. Statistics show that 17 million people die from cardiovascular diseases every year in the world, and more than half of them die from acute myocardial infarction. [0003] Human Urinary Kallidinogenase (Human Urinary Kallidinogenase) is a refined glycoprotein extracted from healthy male urine, with a molecular weight of about 54,000 Daltons. Improve blood circulation, and also increase the deformability of red blood...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/10A61K9/19A61K38/48A61K38/49A61P9/10
CPCA61K9/0019A61K9/19A61K38/4853A61P9/10
Inventor 傅和亮苗丕渠孙铁谢永立
Owner GUANGDONG TECHPOOL BIO-PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com